The most frequent adverse events were mild to moderate injection site reactions. In the Type A SLE group, a total of 34 patients received at least one dose of subcutaneously delivered itolizumab ...

The EQUALISE study is a Phase 1b open-label multiple ascending-dose study of itolizumab in subjects with SLE, with or without active proliferative lupus nephritis (LN). The study is evaluating the ...

Several long-term benefits were observed with itolizumab, including a significant and meaningful improvement in complete response at Day 99, the duration of complete response and failure-free survival ...

The state Health Department has recommended the doctors in all level 2 and 3 hospitals of the state to use dexamethasone or itolizumab injections in place of tocilizumab injection (400 mg), which ...

Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling ...

Equillium, Inc., a clinical-stage biotechnology company, announced the initiation of the EQUATOR study, a pivotal phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease ...

Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium (EQ) evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ...

Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells, is currently in a Phase 3 study for ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo.

Equillium Inc. is forging ahead with regulatory plans for itolizumab in first-line treatment of patients with acute graft-vs.-host disease (GVHD), despite a phase III disappointment. Shares of the La ...

Shares of Equillium (NASDAQ:EQ) cratered 36% Thursday after the company announced it was pausing certain programs due to partner Ono Pharmaceutical failing to exercise an option to acquire its ...